五种JAK抑制剂真实世界疗效与安全性比较:多中心ANSWER队列
基于日本ANSWER队列2013–2025年1798个类风湿关节炎治疗疗程的回顾性多中心研究,比较五种JAK抑制剂因无效和不良事件停药的风险。乌帕替尼和非戈替尼因无效停药风险低于托法替布,且既往IL-6抑制剂或JAK抑制剂暴露的不利影响在这两种药物中不明显。
要点
- 乌帕替尼因无效停药风险低于托法替布(HR 0.33,95%CI 0.24–0.47)。
- 非戈替尼因无效停药风险低于托法替布(HR 0.59,95%CI 0.42–0.85)。
- 既往IL-6i或JAKi使用增加托法替布、巴瑞替尼和培非替尼因无效停药风险。
核心结论
- 真实世界中五种JAK抑制剂因无效和不良事件的停药风险存在差异。
- 乌帕替尼和非戈替尼与更高的治疗持续性相关,且既往IL-6抑制剂或JAK抑制剂暴露的不利影响不明显。
研究设计与样本
- 回顾性多中心研究,使用日本ANSWER队列2013–2025年数据。
- 纳入起始托法替布、巴瑞替尼、培非替尼、乌帕替尼或非戈替尼的RA治疗疗程。
- 共分析1240例患者的1798个治疗疗程。
- 采用Kaplan-Meier分析和多变量Cox比例风险模型(多重插补),调整患者、疾病和治疗特征(包括既往治疗史)。
主要发现
- 因无效停药风险:乌帕替尼HR 0.33(95%CI 0.24–0.47),非戈替尼HR 0.59(95%CI 0.42–0.85),巴瑞替尼HR 0.82(95%CI 0.63–1.06),培非替尼HR 1.23(95%CI 0.89–1.70),均以托法替布为参照。
- 因不良事件停药差异仅见于乌帕替尼(HR 0.57,95%CI 0.38–0.85)与培非替尼(参照)之间。
- 既往IL-6i或JAKi使用增加托法替布、巴瑞替尼和培非替尼因无效停药风险。
- 乌帕替尼既往IL-6i/JAKi的HR分别为0.67(95%CI 0.38–1.16)和1.14(95%CI 0.65–1.98)。
- 非戈替尼既往IL-6i/JAKi的HR分别为0.83(95%CI 0.45–1.53)和1.38(95%CI 0.72–2.65)。
关键数值与推荐
- 因无效停药风险以托法替布为参照:乌帕替尼HR 0.33(95%CI 0.24–0.47),非戈替尼HR 0.59(95%CI 0.42–0.85)。
- 因不良事件停药风险以培非替尼为参照:乌帕替尼HR 0.57(95%CI 0.38–0.85)。
- 既往IL-6i或JAKi使用对乌帕替尼因无效停药HR分别为0.67(95%CI 0.38–1.16)和1.14(95%CI 0.65–1.98)。
- 既往IL-6i或JAKi使用对非戈替尼因无效停药HR分别为0.83(95%CI 0.45–1.53)和1.38(95%CI 0.72–2.65)。
临床怎么用
- 在RA真实世界治疗中,乌帕替尼和非戈替尼可能提供更高的治疗持续性。
- 对于既往接受过IL-6抑制剂或JAK抑制剂的患者,乌帕替尼和非戈替尼的无效停药风险未见明显增加。
局限性
- 本研究为回顾性多中心队列研究,非随机对照设计。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare treatment effectiveness and safety among five Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis (RA) and to identify factors associated with treatment discontinuation in real-world clinical practice. METHODS: This retrospective multicentre study used data from the ANSWER cohort in Japan. RA treatment courses initiating tofacitinib, baricitinib, peficitinib, upadacitinib, or filgotinib between 2013 and 2025 were included. Treatment discontinuation due to ineffectiveness and adverse events was evaluated using Kaplan-Meier analysis and multivariable Cox proportional hazards models with multiple imputation. Analyses were adjusted for patient, disease, and treatment characteristics, including prior treatment history. RESULTS: A total of 1,798 treatment courses from 1,240 patients were analysed. Discontinuation risk due to ineffectiveness was lower with upadacitinib (HR 0.33, 95% CI 0.24 to 0.47) and filgotinib (HR 0.59, 95% CI 0.42 to 0.85) than with tofacitinib (reference), baricitinib (HR 0.82, 95% CI 0.63 to 1.06), and peficitinib (HR 1.23, 95% CI 0.89 to 1.70). Differences in discontinuation due to adverse events were observed only between upadacitinib (HR 0.57, 95% CI 0.38 to 0.85) and peficitinib (reference). Prior IL-6i or JAKi use increased ineffectiveness-related discontinuation for tofacitinib, baricitinib, and peficitinib, but not upadacitinib (IL-6i/JAKi: HR 0.67/1.14, 95% CI 0.38-1.16/0.65-1.98) or filgotinib (HR 0.83/1.38, 95% CI 0.45-1.53/0.72-2.65). CONCLUSIONS: Treatment effectiveness and safety differed among JAKi in real-world clinical practice. Upadacitinib and filgotinib were associated with higher treatment persistence, and the adverse impact of prior IL-6 inhibitor or JAKi exposure was not evident for these agents.
引用
- Etani Y, Okita Y, Tsujimoto K, et al. Comparative effectiveness and safety of five Janus kinase inhibitors in real-world clinical practice: the multicentre ANSWER cohort. Rheumatology (Oxford). 2026. PMID: 42949113. doi:10.1093/rheumatology/keag605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。